INGREZZA improves symptoms and daily functioning in 96% of patients with mild tardive dyskinesia within 4 weeks

A clinician survey found that 90% of patients with mild tardive dyskinesia (TD) experienced impairments in emotional, social, or physical functions. After starting treatment with INGREZZA (valbenazine), 96% of these patients showed improvement in uncontrolled movements, with 86% improving within four weeks. The treatment also led to better overall functional status, independence, daily activities, and work ability. These real-world findings support clinical guidelines recommending INGREZZA for mild TD and highlight its potential to help patients regain independence and improve quality of life.